Clinical Trial Update: High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating high-dose icotinib in advanced non-small cell lung cancer with an EGFR exon 21 mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: NSCLC | Phase 4 | Status: UNKNOWN